Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Fareston
(United States) [Available]Synonyms :
toremifene
Class :
Anticancer & Hormonal agent
Brand Name :
Fareston
(United States) [Available]Synonyms :
toremifene
Class :
Anticancer & Hormonal agent
Dosage Forms & Strengths
Tablet
60 mg
Postmenopausal:
60
mg
Orally
once a day
, continue until disease progression or severe health side effects
180
mg
Orally
once a day
until disease progression or severe health side effects
Dose Adjustments
Use with caution if creatinine clearance is <50 ml/minute
No significant data available for dose adjustment for hepatic impairment
Pediatric
Not determined
Refer to adult dosing
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
when both drugs are combined, there may be an increase in qtc interval serious
QTc interval is increased both by lenvatinib and toremifene
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of toremifene
may increase the QTc interval when combined
may decrease the therapeutic effect of each other when combined
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it may reduce the plasma concentration of CYP3A4 substrates
estrogen receptor agonists (toremifene) may decrease the diagnostic effect of fluoroestradiol F18
it may increase the plasma concentration of CYP3A4 substrates
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may increase the hypercalcemic effect when combined with thiazides
toremifene: they may increase the hypercalcemic effect when combined with thiazides
toremifene: they may increase the hypercalcemic effect when combined with thiazides
toremifene: they may increase the hypercalcemic effect when combined with thiazides
It may enhance the QTc interval when combined with efavirenz
may have an increased thrombogenic effect when combined with c1 inhibitors
the effect of toremifene is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the thrombogenic effect of immune globulin
may enhance the thrombogenic effect of immune globulin
may enhance the thrombogenic effect of immune globulin
may enhance the thrombogenic effect of immune globulin
may enhance the thrombogenic effect of immune globulin
may decrease the therapeutic effect of hyaluronidase
estrogen receptor antagonists decrease diagnostic effect in fluoroestradiol F18
Actions and Spectrum:
Toremifene is a nonsteroidal substance which acts as both an estrogen-like activator and inhibitor. It competes with estrogen to bind to specific sites in breast tumor cells.
Frequency defined:
>10%:
Diaphoresis
Nausea
Vaginal discharge
Hot flash
Increased serum AST
1%-10%
Dizziness
Hypercalcemia
Vomiting
Visual disturbance
Glaucoma
Cardiac arrhythmia
Vaginal hemorrhage
<1%
Angina pectoris
Dyspnea
Toxic hepatitis
Black Box Warning:
None
Contraindication/Caution:
Contraindications
Hypersensitivity
Thromboembolic history
Estrogen receptor-negative tumors
Cautions
Renal impairment
Hypercalcemia
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology:
Toremifene has an antitumor effect and is attributed to antiestrogenic activity. It blocks the effects of estrogen’s growth.
Toremifene also blocks the growth of tumors including apoptosis, regulation, and induction.
Pharmacodynamics:
The drug is indicated as anti-cancer hormonal drug in advanced breast cancer. It has an antiestrogenic effect is competes with estrogen for binding sites in tissues in the breast.
Pharmacokinetics:
Absorption
It has a good absorption rate after oral ingestion.
Distribution
The volume of distribution is around 580 L.
Metabolism
Metabolism occurs in hepatic pathway.
Elimination and Excretion
It is eliminated through feces.
Administration:
It is taken orally as oral dosage form.
Generic Name: toremifene
Pronounced: tor-EM-eh-feen
Why do we use toremifene?
Toremifene is used to treat hormone-receptor-positive metastatic breast cancer in postmenopausal women. It works by blocking the effects of estrogen, a hormone that can promote the growth of certain breast cancer tumors.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
